A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-228 (a Catalytic TORC1/2 Inhibitor) as Single Agent in Adult East Asian Patients With Advanced Nonhematological Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2018
At a glance
- Drugs Sapanisertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda Oncology
- 09 Feb 2018 Status changed from not yet recruiting to recruiting.
- 19 Jan 2018 Planned initiation date changed from 15 Jan 2018 to 22 Jan 2018.
- 19 Dec 2017 New trial record